Creative Planning decreased its position in shares of Aduro Biotech, Inc. (NASDAQ:ADRO) by 13.0% during the second quarter, Holdings Channel reports. The fund owned 13,050 shares of the biotechnology company’s stock after selling 1,950 shares during the period. Creative Planning’s holdings in Aduro Biotech were worth $149,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. State Street Corp increased its stake in Aduro Biotech by 1.3% in the fourth quarter. State Street Corp now owns 573,804 shares of the biotechnology company’s stock worth $6,544,000 after buying an additional 7,597 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Aduro Biotech during the first quarter worth $202,000. Piermont Capital Management Inc. bought a new stake in Aduro Biotech during the first quarter worth $386,000. Norges Bank bought a new stake in Aduro Biotech during the fourth quarter worth $3,266,000. Finally, Bank of New York Mellon Corp increased its stake in Aduro Biotech by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after buying an additional 5,470 shares during the last quarter. 35.60% of the stock is currently owned by institutional investors.

Shares of Aduro Biotech, Inc. (NASDAQ ADRO) traded up 1.79% on Friday, hitting $11.35. The stock had a trading volume of 379,430 shares. The firm’s market capitalization is $846.85 million. Aduro Biotech, Inc. has a 12-month low of $8.75 and a 12-month high of $16.15. The company has a 50 day moving average of $12.44 and a 200-day moving average of $10.98.

Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $5.90 million during the quarter, compared to the consensus estimate of $3.98 million. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The business’s revenue was down 84.9% compared to the same quarter last year. During the same period last year, the business earned $0.03 earnings per share. Equities analysts predict that Aduro Biotech, Inc. will post ($1.37) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Creative Planning Sells 1,950 Shares of Aduro Biotech, Inc. (ADRO)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/08/12/creative-planning-sells-1950-shares-of-aduro-biotech-inc-adro.html.

A number of equities research analysts have weighed in on ADRO shares. BidaskClub raised Aduro Biotech from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research raised Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Tuesday, July 4th. Rodman & Renshaw started coverage on Aduro Biotech in a report on Monday, May 1st. They set a “buy” rating and a $18.00 price objective on the stock. Cowen and Company started coverage on Aduro Biotech in a report on Tuesday, July 18th. They set an “outperform” rating on the stock. Finally, Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $19.00.

In related news, CEO Stephen T. Isaacs sold 10,600 shares of Aduro Biotech stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $10.01, for a total value of $106,106.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Thomas W. Dubensky sold 50,000 shares of Aduro Biotech stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $11.38, for a total transaction of $569,000.00. Following the completion of the transaction, the insider now directly owns 80,812 shares in the company, valued at $919,640.56. The disclosure for this sale can be found here. Insiders sold 618,829 shares of company stock worth $6,803,563 over the last three months. 6.60% of the stock is currently owned by insiders.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro Biotech, Inc. (NASDAQ:ADRO).

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.